Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice

European Heart Journal

Volumn 27, Issue 22, 2006, Pages 2661-2666

  Zeymer, Uwe ^a   Gitt, Anselm K ^a   Jünger, Claus ^a   Heer, Tobias ^a   Wienbergen, Harm ^a   Koeth, Oliver ^a   Bauer, Timm ^a   Mark, Bernd ^a   Zahn, Ralf ^b   Gottwik, Martin ^b   Senges, Jochen ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

Clopidogrel; Primary percutaneous coronary intervention; Prognosis; Reperfusion therapy; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; CARDIOGENIC SHOCK; CLINICAL PRACTICE; CONFIDENCE INTERVAL; DIABETES MELLITUS; FIBRINOLYSIS; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; REVASCULARIZATION; RISK; SEX; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE;

AGED; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; TICLOPIDINE;

EID: 33750901162     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl317     Document Type: Article

References (12)

1. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, Julian D, Lengyel M, Neumann F.-J, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FWA, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
2. ISIS 2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 1988;2:349-360.
3. Herbert JM, Frechel D, Valler E, Kieffer G, Gouy D, Berger Y. Clopidogrel, a novel antiplatelet and antithrombotic drug. Cardiovasc Drug Rev 1993;11:180-198.
4. The CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
5. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol E. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: 2411-2420.
6. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sedon J, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill K, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352: 1179-1189.
7. COMMIT collobarative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621.
8. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montelascot G, Theroux P, Lewis B, Murphy S, McCabe CH, Braunwald E. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction. The PCI-CLARITY Study. JAMA 2005;294:1224-1232.
9. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Vogel C, Gottwik M, Senges J, for the ACOS Study Group. Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the acute coronary syndromes (ACOS) registry). Am J Cardiol 2004;93: 1543-1546.
10. Yusuf S, Mehta SR, Zhao F, Gersh B, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KAA. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972.
11. Budaj A, Yusuf S, Metha SR, Fox KAA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosie MG, for the CURE Trial investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622-1626.
12. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney E, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub W. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the clopidogrel for the reduction of events during observation (CREDO) trial. J Am Coll Cardiol 2005;46:761-769.